Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.50 |
| ▸ | HTR2C | P28335 | 5/20 | 0.47 |
| ▸ | HTR2B | P41595 | 5/20 | 0.47 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29942325 | 0.91 | HRH1 (0.51) | HTR1ASLC6A2TIPARPSLC6A4SLC6A3 | |
| SCHEMBL6964699 | 0.81 | HTR1A (0.49) | HTR1ASLC6A2HTR2CHTR2BTIPARP | |
| Hydrochloric Acid SCHEMBL6966923 | 0.79 | HTR1A (0.48) | HTR1ASLC6A2HTR2CHTR2BTIPARP | |
| SCHEMBL30101464 | 0.79 | KAT2B (0.43) | HTR1ASLC6A2HTR2CHTR2BTIPARP | |
| SCHEMBL30156626 | 0.77 | NTRK1 (0.38) | — | |
| Hydrochloric Acid SCHEMBL31014071 | 0.75 | NTRK1 (0.37) | — | |
| SCHEMBL30101544 | 0.74 | QPCT (0.37) | HTR1ASLC6A2HTR2CHTR2BTIPARP | |
| SCHEMBL30156514 | 0.74 | SLC6A4 (0.33) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL29168668 | 0.74 | SLC6A4 (0.33) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17585072 | 0.73 | CD44 (0.49) | HTR2CHTR2BHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2023-06-22 | — | — | US | disclosed |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | RIBON THERAPEUTICS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HTR1A 942/4885SLC6A2 4604/4885HTR2C 1340/4885 |
| US-11566020-B1 | Pyridazinones as PARP7 inhibitors | PARP2, PARP1, PARP4 | HTR1A 942/4885SLC6A2 4604/4885HTR2C 1340/4885 |
| US-20230192664-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | PARP2, PARP1, PARP4 | HTR1A 942/4885SLC6A2 4604/4885HTR2C 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.